Back to Search Start Over

Investigation of ADAMTS-13 levels in patients with COVID-19 infection.

Authors :
Kutlu HH
Sahin A
Mizrak S
Yilmaz A
Doganay S
Gungor S
Yilmaz S
Source :
Journal of infection in developing countries [J Infect Dev Ctries] 2024 Sep 30; Vol. 18 (9.1), pp. S170-S175. Date of Electronic Publication: 2024 Sep 30.
Publication Year :
2024

Abstract

Introduction: Coronavirus disease 2019 (COVID-19) patients are predisposed to thrombotic events. COVID-19 coagulopathy can be associated with ADAMTS-13 (a disintegrin-like and metalloprotease with thrombospondin type I repeats 13) levels. ADAMTS-13, the cleaving protease of highly thrombogenic ultra-large von Willebrand Factor (vWF) multimers, was rarely investigated in COVID-19 patients and inconsistent results were obtained. We measured ADAMTS-13 levels of patients admitted to emergency department.<br />Methodology: A prospective study was carried out with 180 individuals at the Emergency Department of Uşak Training and Research Hospital. The patients were divided into three groups: mild COVID-19 (group 2), severe COVID-19 with oxygen saturation below 94% (group 3), and control group (group 1). ADAMTS-13 levels were analyzed with an enzyme linked immunosorbent assay (ELISA) kit (SunRed, Shanghai, China). Demographic data, clinical findings, and routine laboratory test results (alanine aminotransferase (ALT), aspartate aminotransferase (AST), white blood cell, lymphocyte, platelet, C-reactive protein (CRP), lactate dehydrogenase (LDH), prothrombin time, international normalized ratio (INR), partial thromboplastin time, D-dimer, creatinine, urea) were evaluated.<br />Results: ADAMTS-13 serum levels were slightly lower in groups 2 and 3 compared to the control group, with no significant difference between the ADAMTS-13 median values (p > 0.05). Groups 1 and 2 exhibited comparable outcomes. Group 3 demonstrated notably elevated levels of CRP, LDH, D-dimer, AST, ALT, creatinine; and decreased platelet counts and INR levels (p < 0.05).<br />Conclusions: COVID-19-associated coagulopathy is still unclear. Based on our data, ADAMTS-13 levels cannot be used as a biomarker to help stratify patients' risks at the time of admission.<br />Competing Interests: No Conflict of Interest is declared<br /> (Copyright (c) 2024 Hüseyin H Kutlu, Arzu Sahin, Soycan Mizrak, Abdurrahman Yilmaz, Songul Doganay, Serdar Gungor, Sema Yilmaz.)

Details

Language :
English
ISSN :
1972-2680
Volume :
18
Issue :
9.1
Database :
MEDLINE
Journal :
Journal of infection in developing countries
Publication Type :
Academic Journal
Accession number :
39499761
Full Text :
https://doi.org/10.3855/jidc.19439